European regulatory frameworks for chemicals (i.e. registered under REACH, plant protection products (PPPs), biocides, human and veterinary medicinal products) require that substances undergo an assessment to identify whether they are persistent (P), bioaccumulative (B) and toxic (T), or very persistent (vP) and very bioaccumulative (vB), i.e. to identify them as PBT substances or vPvB substances according to their properties. We screened current practices, evaluated possibilities and made a proposal for a harmonised assessment. Our proposal assumes that it should be possible to identify PBT and vPvB substances on the basis of the data available according to the requirements of the respective legal frameworks. For substances registered as PPPs and mostly also biocides and medicinal products, a 'definitive assessment' is often possible. Within REACH, the registrant has to provide all information necessary for PBT assessment regardless of the yearly tonnage of chemicals. But in cases of limited data availability, we suggest using a weight of evidence approach to account for such differences in data availability and type of data across different frameworks and to make use of valuable additional information. We propose to base the evaluation of persistence on degradation half-lives and to normalise a number of parameters (e.g. type of kinetics used, temperature). But further work is needed, e.g. for deriving DegT 50 for water and sediment compartments. For the B-criterion, information other than BCF in fish could be considered and more information related to bioaccumulation processes should be gathered (e.g. in species other than fish, different uptake routes). Testing for T identification is focused on standard aquatic species but could also be complemented by e.g. information from other species. Information such as those read-across from structurally related substances and QSAR are often of importance for screening assessments. The aim of PBT and vPvB identification is to reliably target the problematic substances, with as few false negatives or positives as possible, regardless of the regulatory framework. Each aspect was thus considered in the context of the others for a final balanced decision. As the need for conservatism is interpreted differently under the various frameworks, harmonizing this identification is a challenging task.
Background
The different European substance regulations (e.g. REACH [1] , plant protection products regulation [2] , biocidal products regulation [3] , human and veterinary medicinal products regulations [4, 5] ) have all recognised that substances that are either persistent (P), bioaccumulative (B) and toxic (T) (PBT substances) or very persistent (vP) and very bioaccumulative (vB) (vPvB substances) must be considered as hazardous for the environment due to their potential for eliciting long-term adverse effects. The goal of preventing exposure of humans and the environment to PBT and vPvB substances is thus shared among all EU-based regulatory frameworks. In a comparison between different European and International regulations, Moermond et al. [6] reported that there are differences in how this goal is achieved, not only regarding technical criteria but also conceptual criteria (e.g. regulatory consequences for PBT and vPvB substances).
In terms of numerical criteria, the identification of PBT and vPvB substances is based on substance properties which are addressed by the same trigger values in all European substance regulations (see Table 1 ).
Therefore, it could be assumed that the identification of a PBT or vPvB substance should be independent of both the use of the substance and the regulatory framework under which it is assessed. However, the decision on whether a substance fulfils the PBT or vPvB criteria not only depends on substance properties, but also on the framework under which the substance is evaluated. For substances whose properties are near the trigger values, this decision may differ due to differences between the different legal frameworks in (i) The assessment procedures, (ii) The interpretation of PBT/vPvB criteria, (iii) Available data within the assessment process (see next subsection), and (iv) The regulatory consequences Although based on the same principle (i.e. avoiding emissions of potentially harmful substances to the environment), the mandatory measures imposed by regulation for a substance identified as a PBT or vPvB vary between the different regulatory frameworks:
-For substances registered under REACH, the revised Annex XIII [7] not only gives the criteria but also the information relevant for the screening and assessment of P, vP, B, vB and T properties. Also, ECHA provides extensive guidance on PBT/vPvB assessment [8, 9] . Substances of very high concern (SVHC) (e.g. PBT/vPvB) are included in the 'candidate list' for authorisation, based on the outcome of the scientific assessment of intrinsic properties. Substances on the 'candidate list' can then be prioritised for authorisation and finally listed in Annex XIV of the REACH regulation. Some substances may be listed with specific exemptions that do not require authorisation. For each substance included in Annex XIV, a deadline will be set after which use of that substance in the EU must stop (known as the 'sunset date'), unless authorized by the European Commission. -The EU Biocidal Products Regulation [3] refers to Annex XIII of REACH [7] and to the ECHA guidance for PBT/vPvB assessment [8, 9] . However, for biocides, generally no authorisation will be granted for products containing substances identified as PBT or vPvB. Additionally, biocides that fulfil two of the three criteria are flagged as candidates for substitution and are subjected to a comparative assessment. -For the assessment of veterinary medicinal products, guidance has been developed by the European Medicines Agency [10] , which also refers to ECHA guidance [8, 9] . A benefit-risk analysis is conducted in support of the decision on whether to authorise the substance or not [5] . In this context, an identification as a PBT substance is generally regarded as a serious concern. -For medicinal products for human use (which are usually emitted via sewage treatment plants), no restrictions are envisaged as human health is prioritised over environmental issues [4] . ECHA guidance [8, 9] is used for the assessment. -By contrast, the PPP Regulation [2] simply stipulates the PBT/vPvB criteria, oblivious to any other guidance. As for biocides, no authorisation will be granted for those substances identified as PBT or vPvB. Additionally, PPPs that fulfil two of the three criteria are flagged as candidates for substitution and are subjected to a comparative assessment, as is the case for biocides. The draft guidance developed by DG Sanco [11] focuses primarily on the identification of candidates for substitution.
Although the substances differ in their properties, uses, exposure pathways and regulatory consequences, • Half-life (degradation) > 180 days in marine sediment, or
• Half-life (degradation) > 180 days in marine, fresh or estuarine sediment, or • Half-life (degradation) > 120 days in fresh or estuarine sediment, or
• Half-life (degradation) > 120 days in soil
• Half-life (degradation) > 180 days in soil the outcome of a PBT/vPvB assessment should not depend on the framework under which they are evaluated, since the protection goals do not differ. This will avoid situations where a substance with different uses is identified as a PBT substance under one regulation, and not under another. This is relevant because, for example, many biocides are also used as PPPs or veterinary medicinal products. Since regulatory authorities should aim at making predictable and consistent decisions, a strategy for harmonised PBT identification across the different frameworks is needed. The focus of this paper is on the assessment procedure; it proposes a reasonable interpretation of the available data while considering not only substance properties but also keeping in mind the regulatory consequences.
Dealing with differences in data requirements and data availability between regulatory frameworks
For substances registered as plant protection products (PPPs), as well as most biocides and medicinal products, requirements for environmental risk assessment usually include sufficient information for PBT/vPvB identification. Therefore, a 'definitive assessment' based on a direct comparison to the trigger values (see Table 1 ) of the three criteria should be possible in most cases. For chemicals registered under REACH, data requirements depend on the quantities which are manufactured or imported per year; for high production volume (HPV) chemicals, more data has to be provided, and for substances below 10 t/a, only a basic data set is mandatory. Table 2 provides an overview of test requirements for persistence. The registrant also has to provide all information needed for PBT/vPvB assessment regardless of the tonnage manufactured or imported annually. However, the necessary information is not always included in the dossiers so a direct comparison of measured data with the criteria is not always possible. Unfortunately, in many cases, registrants submitted dossiers which show deficiencies and do not comply with the requirements of REACH or the Technical Guidance Document, e.g. necessary tests are missing [12, 13] . In such cases, only a 'screening assessment' can be performed. In such an assessment screening information such as that listed in Annex XIII of REACH [7] should be considered; this should be supplemented by data from non-standardised tests and from the literature, by information on relevant endpoints based on quantitative structure-activity relationships (QSARs) if adequately documented as well as by read-across from structurally related substances or grouping approaches. Only if the available information is considered unreliable or insufficient and/or does not permit a conclusion on each criterion to be drawn with sufficient confidence, additional testing will be necessary.
Because of the large differences in data requirements across the different frameworks and type of data (e.g. QSARs, non-standardised tests), we recommend considering all available information in a weight of evidence (WoE) approach -as suggested in REACH (Annex XI 1.2 of [1]). The WoE approach means that all available information is assessed through expert judgement for its suitability and reliability, and relative weights are assigned (e.g. quality of the data, consistency of results and/or data, nature and severity of effects, relevance of the information for the given regulatory endpoint). The use of this WoE approach depends on the amount of information needed, the importance of the decision to be taken, and Required for all substances > 10 t/a One simulation study in the 'compartment of concern' required for all substances >100 t/a if not readily biodegradable Not required the likelihood and consequences of taking a wrong decision [14] . The WoE approach also has the advantage, such that it uses valuable additional information whose submission is not mandatory (e.g. field data, alternative testing strategies). This approach is proposed in REACH, and we suggest that it should also be used to improve PBT assessment under the other frameworks in cases where it could deliver valuable additional information.
Discussion
Persistence, bioaccumulation and toxicity criteria
In this chapter, we introduce the three criteria, i.e. persistence (P), bioaccumulation (B) and toxicity (T). The general scheme is to test sequentially for P, then B and lastly for T, as only substances with high persistence must be considered further for PBT identification. This sequence is further justified by the need to limit testing for animal welfare reasons.
A substance is considered a PBT or vPvB substance if it fulfills the P, B and T or the vP and vB criteria. In the following sections, for each PBT criterion, the criteria for the 'definitive assessment' are presented first. This is followed by the criteria for the 'screening assessment' , which is carried out in cases of limited data availability.
Persistence
The persistence of a substance in soil, water or sediment is controlled by its intrinsic properties and also influenced by environmental conditions (e.g. temperature, presence of degraders, pH, moisture content in case of soil, bioavailability of the substance). The assessment of persistence is influenced by the type and quality of available studies and also by the interpretation of the available data.
Persistence is not characterised consistently in the different frameworks, but, as suggested by Boethling et al. [15] and in [9] , it is the degradation half-life (DegT 50 ) which should be compared to the trigger values in the various compartments, as a mere transfer (dissipation) from one compartment to the other does not affect the persistence of a substance. DegT 50 values are commonly estimated from the parent substance in extractable residues in degradation simulation studies performed according to e.g. OECD test guidelines 307, 308 or 309 [16] [17] [18] .
In the context of PBT identification, DT 50 should not refer to dissipation half-lives (DissT 50 ) as these refer to cases where the substance may not be degraded but only redistributed (e.g. from the water phase to sediment or the atmosphere, or leaching, run-off, volatilisation or uptake into plants). This is explicitly mentioned in the revised Annex XIII of the REACH regulation [7] , while the PPP Regulation [2] only refers to half-lives in general.
Definitive assessment. If degradation simulation tests have been conducted to meet legal requirements, a sufficient amount of reliable data is usually available to complete a definitive assessment by comparing the DegT 50 values directly to the criteria as reported in Table 1 . However, a number of issues related to these values should be addressed.
Type of kinetics for deriving DegT 50 . We suggest using single first-order (SFO) kinetics to derive DegT 50 values for the purpose of comparing them to the trigger values. Best fit kinetics such as first-order multicompartment (FOMC) can be used if they are recalculated by dividing the DegT 90 values by a factor of 3.32 or by using the degradation rate constant of the slower phase in case of double first-order in parallel model (DFOP) or Hockey stick (HS) kinetics. This proposal is based on the Guidance Document on Estimating Persistence and Degradation Kinetics from Environmental Fate Studies on Pesticides in EU Registration [19] . This document gives detailed guidance on the derivation of DegT 50 values, which is used for risk assessment of biocides, medicinal products and PPPs and could be applied to other substance groups as well.
Normalisation of the DegT 50 to specific conditions. Variable conditions such as temperature, humidity, microbial populations and others have a large influence on the rate of degradation of a chemical substance. Simulation studies in the laboratory are conducted at various temperatures: OECD test guidelines 307 and 308 on transformation in soil and in water-sediment systems [16, 17] recommend testing at 20°C and 10°C (if the substance is used in colder climates), the US EPA recommends 22°C for soil testing [20] and for many pesticides, tests have been performed both at 20°C and 10°C. For the purpose of comparing different data, half-lives should thus be normalised to a defined temperature since it is a criterion which strongly influences the outcome of a degradation test and, furthermore, is quantifiable unlike other related criteria such as differences in microorganism populations. For PBT identification, normalisation of DegT 50 values to a temperature of 12°C has been applied to many biocides and other chemicals, as prescribed in the TGD [21] , and is included as an option in the REACH guidance on information requirements and chemical safety assessment (Chapter R.7b [8] ). This temperature of 12°C is also included in the draft 'Guidance on the assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicine' [22] . By contrast, DegT 50 values for PPPs are normalised to 20°C, both for laboratory and field data for risk assessment; this temperature has also been proposed for PBT identification [11] . For a consistent approach between frameworks, we propose normalising the DegT 50 values to 12°C because this temperature is established or suggested under the majority of frameworks (i.e. Biocides Regulation, REACH and medicinal products Directives).
Degradation in soil: inclusion of field studies. Laboratory simulation studies can provide information on both route and rate of degradation. This permits the estimation of primary degradation rates (DegT 50 ), as well as the measurement of carbon dioxide evolution and of formation of metabolites and bound residues. But the small size of the test systems is a limiting factor for both the test duration and the diversity of the microbial population (which may limit the probability of having competent degraders and which usually also decreases over time).
For PPPs, terrestrial field (dissipation) studies under realistic outdoor conditions are required when the DegT 50 exceeds 60 days at 20°C in laboratory studies [2] . Such field studies allow DT 50 values to be derived under conditions going beyond the limitations of laboratory tests. A number of conditions may be more realistic compared to laboratory studies (e.g., prolonged duration, fluctuating temperature and humidity, higher biological activity, larger test system), but may not be as easy to compare or reproduce. A limiting aspect in such testing is that a dissipation half-life, and not a degradation half-life, will be derived. The measured residues result from biotic degradation but also from photolytic transformation and field dissipation processes like volatilisation, leaching and runoff. However, a novel approach to estimate a DegT 50 in field studies has recently been proposed by EFSA [23] in which dissipation processes on the soil surface are estimated separately from biodegradation in the soil compartment. This DegT 50 has to be normalised for temperature and humidity for comparability reasons. Although this guidance was developed for the evaluation of persistence of PPPs in field studies, in principle, its rationale and approach should also be applicable to other types of substances. Thus, we suggest including field studies in persistence assessment as additional data, provided that it is possible to derive DegT 50 values. This is in line with the WoE approach, which considers all available information in the decision process.
Evaluation of DegT 50 values for the water and sediment compartments. There is no standardised test that measures true degradation only in the sediment compartment. The test on 'aerobic and anaerobic transformation in aquatic sediment systems' (OECD test guideline 308 [17] ) is generally used to assess the fate of compounds in water and sediment systems, but reliable separate DegT 50 values for water and for sediment cannot usually be derived from the study results. Therefore, separate
DegT 50 values are generally not available for comparison with the trigger values.
Available DT 50 values for the water phase in many cases only refer to dissipation, as many substances, especially those with high log K OC and low water solubility, are quickly transferred to the sediment. The Aerobic Mineralisation in Surface Water -Simulation Biodegradation Test (OECD 309 [18] ) is available to measure degradation in the water phase, but to date it has rarely been used for the assessment of environmental fate.
We suggest comparing the DegT 50 of the total system to the two trigger values for water and sediment. More specifically, in the case of a substance that is rapidly transferred into the sediment, the DegT 50 of the total system should be compared with the trigger value for sediment (120 and 180 days for persistence assessment). For substances that mostly remain in the water phase, the DegT 50 values should be compared with the trigger values for water (40 and 60 days for persistence assessment). There will be many cases where a substance can be found in both the water and sediment phases, which means that clear criteria are necessary to judge which of the trigger values is appropriate.
Selection of an adequate DegT 50 from multiple studies. As explained above, testing requirements for persistence differ greatly between regulatory frameworks. The information is summarized in Table 2 .
If several valid degradation studies for one compartment are available, their quality and reliability are an important consideration. We propose the following approach to processing the information gathered: If five or more DegT 50 values are available, we suggest selecting the geometric mean. This is to be considered together with the decision to normalise the DegT 50 values to a temperature of 12°C, in order to achieve an overall reasonable conservatism (i.e. target the problematic substances).
This choice is illustrated by the evaluation of a number of substances (64) with 5 and more soil laboratory DegT 50 values available, whose the degradation data have been recently assessed as part of the regular national PPP registration process in Germany. This exercise indicates how many substances would be identified as P, on the basis of the above evaluation parameters.
-For degradation in soil, only data from laboratory studies was used. Field studies were excluded since no evaluations according to the new EFSA scientific opinion [23] were available yet. -For water-sediment studies, the total system DegT 50 was used and compared to the sediment value of 120 days. -Temperature was normalised both to 12°C and 20°C; -The maximum DegT 50 value (worst-case scenario) and the geometric mean of all DegT 50 were used.
The results indicate that the percentage of substances fulfilling the P criterion varies from about 39% for the least conservative approach (20°C and geometric mean) to 73% for the most conservative approach (12°C and maximum DegT 50 ) and is intermediate (i.e. about 53%) when the geometric mean and a temperature of 12°C are used (Table 3) .
Screening assessment
For many chemicals, especially those registered under REACH, only a limited data set is available, as explained in Chapter 2. In this case, the assessment of persistence has to be based on screening data. If no further data are presented, the result of the screening assessment (i.e. screening P) should be used for further regulatory action unless refuted by more definitive data such as valid simulation test data.
In the screening approach, the evaluation of persistence is mainly based on tests on ready biodegradability (OECD 301 A-F [24] and OECD 310 [25] ).
Substances which are readily degradable are considered not to be persistent (not P) [26] , as the test is fairly stringent. Due to the high rate of mineralisation, an accumulation or formation of relevant metabolites is improbable. On the other hand, substances that are not readily biodegradable are considered to be potentially persistent (potentially P, sometimes also called 'screening P'), until further data are presented. Due to the stringency of the test, this results in a high number of false positives; thus, 'enhanced ready biodegradability' tests (based on ready biodegradability tests but with prolonged test duration, higher concentration of microbial biomass, increased test volumes, but no pre-adaptation) may be used for chemicals registered under REACH to prove their degradability without having to conduct more expensive and timeconsuming simulation studies.
Other available data on persistence also have to be examined. This may include data on abiotic degradation, monitoring data, QSAR estimations and read across from structurally related substances.
Main outcomes and open points
Our proposal is to base P identification on degradation, and not on dissipation, as recommended previously [6, 17] . Thus, trigger values should be compared to DegT 50 values. The final identification of substances as persistent should be based on a reasonable conservatism for the various regulatory frameworks and not on a combination of various worst-case choices. Our proposal is summarised in Table 4 .
It should be noted that in the P assessment, other information generated in degradation simulation studies such as the formation of non-extractable residues (NER) or the mineralisation rate are not formally considered. Such information can only be taken into account in a This evaluation was performed with a dataset of 64 PPP.
WoE approach but should not be ignored. Where NER are the result of degradation and incorporation into the microbial biomass, their formation can be considered as a detoxification step. On the other hand, where the original substance may be remobilised, NER formation should be interpreted as a specific form of compound persistency. The issue of NER is currently being examined in various contexts [27] [28] [29] .
Bioaccumulation
Substances with a high potential for bioaccumulation are of special concern even if introduced into the environment in low concentrations. They are taken up by biota and their concentrations in the tissues result from the combination of uptake and depuration. Uptake occurs either via the surrounding medium -water or soil -(bioconcentration), food (dietary bioaccumulation) or the food chain (biomagnification). These processes are driven by the properties of the substance (mostly hydrophobicity as determined by octanol/water or octanol/air partition coefficient, i.e. K OW or K oa , as well as other characteristics, e.g. protein-binding properties) but they also depend on the environmental matrices (i.e. aquatic, terrestrial) and on the biological, ecological and trophic characteristics of the organisms. The bioconcentration factor (BCF) is the usual basis for defining the B criterion in PBT assessment although it is not always the most relevant indicator of the environmental bioaccumulation potential of a substance, as stated in [30] . Indeed other available data (e.g. monitoring data, biomagnification, bioaccumulation in other species, literature data) should also be taken into account [30] [31] [32] . We propose therefore that all available relevant information on bioaccumulation should be considered in a WoE approach.
Definitive assessment. The definitive assessment of the bioaccumulation potential is based on the bioconcentration factor (BCF) in an aquatic species. The trigger value for the BCF is set at >2,000 L/kg for B assessment and at >5,000 L/kg for vB assessment.
Bioconcentration. The bioconcentration factor (BCF) is defined as the ratio of concentration in fish to the concentration in the surrounding medium. It is generally derived experimentally according to OECD Test Guideline 305 I (bioconcentration flow-through fish test [33] ). This test is appropriate for substances with moderate hydrophobicity, so it is necessary to determine the concentration of the test substance in the exposure medium and in fish. The test is mandatory for risk assessment for PPPs, biocides and human medicinal products if log K OW exceeds 3, and for veterinary pharmaceuticals if log K OW exceeds 4. It is also required for REACH substances with a production volume above 100 t/a and a log K OW >3.
The BCF should be normalised to a lipid content of 5% of total body weight (average lipid content of fish commonly used in [33, 34] ). Potential growth dilution should also be taken into account [26, 33] , as well as indications of slow or poor depuration.
Bioaccumulation and biomagnification. Bioaccumulation and biomagnification should also be taken into account for species such as fish since the relevant route of exposure may be the food, especially for substances with high log K OW and for substances poorly soluble or nonsoluble in water. Indeed for such substances, it may be technically difficult or not feasible (i) to conduct a bioconcentration fish test since aqueous exposure via gill The P and vP criteria are included for definitive and screening assessments.
uptake is reduced and no longer accounts for the dominant exposure pathway, and/or (ii) to analyse the concentration in water. Instead, a dietary fish test has been developed to determine uptake by ingestion, yielding a biomagnification factor (BMF) [33] .
A BMF >1 is a supportive indication of high bioaccumulation and the B criterion is thus considered as fulfilled. Nevertheless, a definitive trigger value for BMF has not yet been established. Hence, a bioaccumulation potential cannot be excluded in cases of BMF < 1. Recalculation of the dietary study data into aquatic BCF values has been suggested [26] but these methods have to be checked carefully for their domain of applicability [35] .
Supplementary information. Other reliable data should also be considered, when available:
-High bioaccumulation in organisms other than fish, as mentioned in the Stockholm Convention [36] and the revised Annex XIII criteria in REACH [7] ; e.g. bioaccumulation in mussels [37] or oligochaetes [38] . In some cases, lipid normalisation concentrations should be revised since a normalisation to a lipid content of 5% of the body weight -as proposed for fish (see above) -may not be suitable for species with low lipid content (e.g. mussels); -Indicators other than BCF calculated from environmental data (i.e. measured in mesocosms or in the field), assessing the accumulation of substances from water and diet such as the bioaccumulation factor (BAF), their specific accumulation in food webs expressed as biomagnification factor (BMF) or trophic magnification factor (TMF); -Bioaccumulation via different uptake routes, e.g. terrestric or benthic oligochaetes [38, 39] . As bioaccumulation may differ between water-and air-breathing organisms, aquatic bioaccumulation data should not be transfered to air-breathing organisms [31] ; -Accumulation in specific tissues, e.g. substances such as PCBs accumulate extensively in fatty tissues and organs from wildlife samples [40] . In some cases, inefficient or nonexistent detoxification processes may be responsible for high BCF values (e.g. TBT in molluscs) [41, 42] . -Non-lipid-based accumulation for substances such as perfluorinated acids, which bioaccumulate in blood plasma proteins [43, 44] . Perfluorooctane sulfonate (PFOS) can be considered as bioaccumulative even though the BCF is below the trigger value (<2,000) but it has a long half-life, high toxicity and high biomagnification.
-Toxicokinetic and chronic studies with mammals as well as in vitro data on aquatic bioaccumulation as required for human toxicological assessment are also available.
Screening assessment. The screening criterion for assessing bioaccumulative properties is derived from the hydrophobicity of the compound. A substance is considered to potentially fulfil the B criterion when log K OW exceeds a value of 4.5 [21] . Suitable quantitative structure-activity relationship (QSAR) models for estimating the BCF could be used if log K OW is between 4.5 and 6, as the available BCF QSAR models are linear between log K OW 2 to 6 [21, 45] . For highly hydrophobic substances (log K OW > 6), the potential for bioaccumulation must be assessed through expert judgement and on a case-by-case basis, taking into account the specific physico-chemical properties of the substance (e.g. molecular size and weight, log K OW ) and the available BCF QSAR models (e.g. parabolic equation in [21, 46] ).
Since hydrophobicity does not drive all bioaccumulation processes, other information has to be considered, e.g. surface activity, structural alerts, high log K OA (octanol/air partition coefficient) as an indicator of a possible bioaccumulation in air-breathing organisms or read-across approaches from structurally related substances.
Main outcomes and open points. Our proposal (see Table 5 ) is to consider all available endpoints in addition to the BCF for aquatic organisms in the WoE approach, as there are other standardised tests resulting in the derivation of other BAFs (e.g. benthic oligochaetes [38] ; terrestric oligochaetes [39] ) and BMFs (fish dietary test guideline [33] ). Currently, a comparison between the results of these tests (e.g. BMF, BAF) and a BCF is difficult to make for several reasons such as different uptake mechanisms of different taxa. Also, in vitro tests for bioaccumulation (e.g. [47] ) are being developed and using information from field studies and TMF (e.g. [42, 48] ) is being considered. Taking into account these various aspects will improve the assessment of bioaccumulation.
Toxicity
For substances with high persistence and bioaccumulation potential, i.e. fulfilling the P and the B criteria, longterm exposure of organisms can be expected, which may cover the whole life-span of the exposed organisms and even several generations. Therefore, long-term and/or chronic ecotoxicity data, ideally covering the reproductive stages, should be used for assessing the T criterion in the context of a PBT assessment.
Definitive assessment The substance fulfils the T criterion in any of the following situations:
1. Long-term or chronic NOEC or EC 10 values from ecotoxicological tests with aquatic organisms are below the trigger of 0.01 mg/L, or 2. It is classified as carcinogenic, categories 1 and 2 [49] or 1A and 1B [50] , mutagenic, categories 1 and 2 [49] or 1A and 1B [50] or toxic for reproduction, categories 1, 2 and 3 [49] or 1A, 1B and 2 [50] , so-called CMR substances, or 3. There is other evidence of chronic toxicity, as identified by the classification of the substance as T, R45, R46, R48, R60 and R61 or Xn, R48, R62, R63, R64 [49] , or specific target organ toxicity and repeated exposure (STOT RE category 1 or 2) [50] .
If any classification criteria under 2 or 3 are met, there is no need to perform any further aquatic studies for evaluation of toxicity.
Supplementary information. When substances such as PPPs and biocides (i.e. produced to control pests) are tested for toxic effects, it is likely that these will occur both in the target species and in non-target species belonging to the same taxonomic group. Testing for the T criterion refers only to aquatic organisms. However, effects on non-aquatic species could be relevant as well, bearing in mind, however, that the use of vertebrates for testing should generally be minimised.
In this context, we recommend that other reliable data should also be considered where available:
-For PPPs and biocides, results of subchronic, chronic or reproduction studies with birds and mammals may be available. In this context, a NOEC of ≤30 mg/kg food in a long-term bird study should be considered as an indication that the T criterion is met [21, 26] . -It could be relevant to use toxicity data from longterm ecotoxicological tests on terrestrial organisms, e.g. OECD TG 222 [51] . However, in such a case, it has to be clarified whether such an assessment should (i) be based on trigger values comparable to those used in the assessment of toxicity for aquatic organisms (e.g. <0.01 mg/kg dry soil), and (ii) take into account differences in the exposure of the respective organisms. -For substances with high log K ow , tests performed with sediment-dwelling species may provide better information than tests with pelagic species. Indeed, the results may be more reliable if the substance partitions out of solution. Also, the information gathered may be more useful if it is focused on the compartment in which the substance will likely be found. A way to determine whether a substance has equivalent toxicity in sediment as in the water column should be proposed.
Furthermore, information on aquatic toxicity other than that gathered from standard studies and provided for in relevant test guidelines, i.e. information from nonstandard studies and non-standard endpoints, could be used as supporting data. Also, the endocrine disrupting potential of chemical substances is an issue. It is planned to develop a general concept for EDCs which should be consistent and should ensure that endocrine disruptors are dealt with in a consistent and coordinated manner across the different regulatory frameworks [52] . This issue has been discussed by a panel of experts of the German In vitro data on aquatic bioaccumulation
The B and vB criteria are included for definitive and screening assessments.
Federal Environment Agency (UBA) [53] . This could be considered for inclusion of EDC potential in the harmonised assessment of the T criterion.
Screening assessment. The screening criteria for assessing toxicity are based on short-term (acute) toxicity of the compound on aquatic organisms. They are as follows: 10 values from prolonged or chronic toxicity studies will always be below acute LC 50 or EC 50 values for the same taxon [26] .
Other possibilities include the use of QSAR and readacross from structurally related substances, if testing of the substance is technically impossible because of its physicochemical properties or in cases of data poor situations.
Main outcomes
The criteria for the definitive and the screening assessment of the T criterion are to a large extent consistent between the different regulatory frameworks. However, in situations where data availability or adequacy is too poor to support a definitive or a screening assessment, we propose that other indications of toxicity potential should be taken into account (Table 6 ). These include, for example, endpoints from toxicity tests with terrestrial organisms, endocrine-disrupting properties, QSAR calculations or harmonised toxicological classifications. Since trigger values have not yet been set for these endpoints, a WoE approach is needed to decide on a case-by-case basis whether a substance fulfils the T criterion as part of PBT assessment.
Considering metabolites and transformation products
Transformation products can be as or even more persistent than their parent compounds and thus must be included in chemical assessment. However, the regulatory frameworks for substances differ with respect to the inclusion of metabolites or transformation products in PBT identification. For PPPs, the consideration of metabolites in the context of PBT identification has been controversially discussed, as PPPs Regulation 1107/2009 [2] does not address this issue precisely and only refers to the relevance of metabolites in a general sense (Art. 3 (32) Annex II point 3.3). However, a current proposal envisages excluding metabolites in the process of PBT identification and in the identification of candidates for substitution (i.e. substances that meet two of the three criteria) [11] . REACH requires that registration documents for chemicals produced or imported in excess of 100 t/a include information about metabolites and transformation products [54] . They are to be considered in PBT identification if they exceed 0.1% of the substance weight [9, 26] . For both human and veterinary medicinal products, transformation products >10% are considered to be 'relevant' and thus included in risk assessment as well as in PBT assessment. In the assessment of biocides, major metabolites (≥10% or ≥5% at two consecutive sampling points or maximum not reached but ≥5% of the active substance at the final time point) are considered in PBT identification and minor metabolites only if data are available or there is any reason for concern. It is questionable whether relevance can be defined in terms of any percentage. Since humans and the environment should be protected from exposure to PBT and vPvB substances, the same criteria should apply to metabolites or transformation products as to the parent compounds. We suggest that in all regulatory frameworks, metabolites and transformation products should be included in the assessment.
Conclusions
The various European regulatory frameworks on chemical substances agree that exposure of humans and the environment to substances identified as PBT or vPvB must be avoided. But the decision-making process is not straightforward and harmonisation between the frameworks is a 
Endocrine-disrupting potential
The T criteria for definitive and screening assessments is included.
real challenge. Indeed, despite the same trigger values, the identification of a PBT or vPvB substance will depend on how the criteria are used in the various frameworks to determine.
(i) For persistence, the half-lives in terms of e.g. temperature normalisation, how field studies are considered, appropriate statistics, and others, (ii) For bioaccumulation, e.g. the endpoints -in addition to the BCF for aquatic organismsconsidered in a WoE approach, and (iii) For toxicity, e.g. indications of toxicity potential considered when availability or adequacy of data is too poor to support a definitive or a screening assessment.
Differences in testing requirements, data availability, data evaluation and interpretation were screened and discussed to identify the best methods. The current proposal is thus characterised by its robustness against those differences and by its reasonable conservatism.
For example, the proposal for the Persistence criterion is based on the outcome of an evaluation performed on a set of selected active substances of PPPs. We recommend (i) normalising the DegT 50 values to a temperature of 12°C as this is established in biocides legislation and suggested in other regulations (REACH and medicinal products directives), and (ii) selecting the geometric mean if five or more DegT 50 values are available, or a suitable value or range of DegT 50 values in a WoE approach if the studies are not equally reliable.
Finally, the differing mandatory measures imposed by the various regulations should be considered together with the present proposal on harmonised PBT/vPvB identification in order to ensure that the truly problematic substances are identified. 
